SCHEMBL3934485

SCHEMBL3934485

NC(=O)C1(N2CCCC2)CCN(Cc2ccccc2)CC1

nearest known ligand 0.97

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.97
ALDH1A1 P00352 5/20 0.74
TP53 P04637 1/20 0.59
CYP2D6 P10635 2/20 0.59
KDM4E B2RXH2 2/20 0.58
MAPT P10636 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
CHRM2 P08172 2/20 0.54
HTR1A P08908 2/20 0.54
ADRA2A P08913 2/20 0.54
DRD1 P21728 2/20 0.54
SLC6A4 P31645 2/20 0.54
ADRA1A P35348 2/20 0.54
OPRM1 P35372 2/20 0.54
DRD3 P35462 2/20 0.54
SLC6A3 Q01959 2/20 0.54
KCNH2 Q12809 2/20 0.54
HRH3 Q9Y5N1 2/20 0.54
CHRM1 P11229 1/20 0.54
TBXA2R P21731 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4630100 0.99 TSHR (1.00) TSHRALDH1A1TP53CYP2D6KDM4E
Isophthalic Acid SCHEMBL27532027 0.89 TSHR (0.82) TSHRALDH1A1TP53CYP2D6KDM4E
SCHEMBL18425029 0.88 TSHR (0.77) TSHRALDH1A1CYP2D6KDM4ESMN1; SMN2
SCHEMBL4630891 0.88 TSHR (0.76) TSHRALDH1A1TP53CYP2D6KDM4E
SCHEMBL2335020 0.88 TSHR (0.76) TSHRALDH1A1TP53CYP2D6KDM4E
SCHEMBL4610975 0.87 TSHR (0.80) TSHRALDH1A1TP53CYP2D6KDM4E
SCHEMBL6706403 0.87 TSHR (0.80) TSHRALDH1A1CYP2D6KDM4ECHRM2
Hydrochloric Acid SCHEMBL6504677 0.86 TSHR (0.78) TSHRALDH1A1TP53CYP2D6KDM4E
SCHEMBL4610565 0.84 TSHR (0.71) TSHRALDH1A1CYP2D6SMN1; SMN2CHRM2
SCHEMBL4610766 0.83 TSHR (0.74) TSHRALDH1A1CYP2D6KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572913-B2 Inhibitors of Rho kinase; N-Benzyloxycarbonyl-4-[N''-(tert-butyloxycarbonyl)hydrazino]piperidine; 4-{[N''-(tert-butyloxycarbonyl)-N'-(1'-propyl)]hydrazino}piperidine BIOAXONE THERAPEUTIQUE INC. (CA) 2009-08-11 US disclosed
EP-1720874-A1 4-SUBSTITUTED PIPERIDINE DERIVATIVES Bioaxone Therapeutique Inc. (CA) 2006-11-15 EP disclosed
US-20050272751-A1 4-Substituted piperidine derivatives BIOAXONE THERAPEUTIQUE INC. (CA) 2005-12-08 US disclosed
WO-2005080394-A1 4-SUBSTITUTED PIPERIDINE DERIVATIVES BIOAXONE THERAPEUTIQUE INC. (CA) 2005-09-01 WO disclosed
EP-1047673-A1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 2000-11-02 EP disclosed
US-6048856-A ANALGESICS; ANTIINFLAMMATORY AGENTS NOVO NORDISK A/S (DK) 2000-04-11 US disclosed
WO-1999031058-A1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 1999-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272751-A1 4-Substituted piperidine derivatives RHOC, PRPH, RHOT2 TSHR 1467/4885ALDH1A1 1701/4885TP53 4092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.